ID
45157
Descripción
Principal Investigator: Alan Shuldiner, MD, University of Maryland Baltimore, Baltimore, MD, USA MeSH: Pharmacogenomics,Clopidogrel,Platelets https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000391 CHD is the leading cause of death in the United States. One of the most common ways to prevent CHD is to take an anti-platelet agent, which lessens platelet aggregation. Two of the most common anti-platelet agents are aspirin and clopidogrel. However, up to 25% to 30% of people do not respond to these medications. Evidence indicates that treatment response may be related to genetics. The purpose of this study is to determine specific gene variants that predict response to aspirin and clopidogrel therapy. This study is part of a larger group of studies called the Pharmacogenomics Research Network (PGRN). Participants are from the Old Order Amish of Lancaster, Pennsylvania. They are well suited for genetic studies because they are a homogenous, closed, founder population. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before and after clopidogrel alone, and then again after taking clopidogrel plus aspirin. Using the gene variation profiles across the genome, researchers analyzed which variants correspond to treatment response.
Link
Palabras clave
Versiones (2)
- 2/9/22 2/9/22 - Niko Möller-Grell
- 12/10/22 12/10/22 - Adrian Schulz
Titular de derechos de autor
Alan Shuldiner, MD, University of Maryland Baltimore, Baltimore, MD, USA
Subido en
12 de octubre de 2022
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000391 Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study
Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID and sample ID of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID, age, sex, body mass index, systolic and diastolic blood pressure, waist circumference, fasting triglycerides, total cholesterol, LHD, HDL, baseline whole blood max aggregation of ADP, of arachidonic acid, and collagen 1, post plavix/pre aspirin whole blood max aggregation of ADP, of arachadonic acid, and collagen 1, baseline platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, and arachadonic acid, post plavix/pre aspirin platelet rich plasma max aggregation of ADP, of Epi, and arachadonic acid, post plavix/post aspirin platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, of arachadonic acid obtained from participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
Similar models
Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID and sample ID of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID, age, sex, body mass index, systolic and diastolic blood pressure, waist circumference, fasting triglycerides, total cholesterol, LHD, HDL, baseline whole blood max aggregation of ADP, of arachidonic acid, and collagen 1, post plavix/pre aspirin whole blood max aggregation of ADP, of arachadonic acid, and collagen 1, baseline platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, and arachadonic acid, post plavix/pre aspirin platelet rich plasma max aggregation of ADP, of Epi, and arachadonic acid, post plavix/post aspirin platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, of arachadonic acid obtained from participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.